Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2024 Dec 30;19(12):e0315511. doi: 10.1371/journal.pone.0315511

Protective role of Pannexin1 in lymphatic endothelial cells in the progression of atherosclerosis in female mice

Avigail Ehrlich 1,2, Graziano Pelli 1,2, Bernard Foglia 1,2, Filippo Molica 1,2,#, Brenda R Kwak 1,2,*,#
Editor: Eliseo A Eugenin3
PMCID: PMC11684638  PMID: 39775604

Abstract

Atherosclerosis is a progressive arterial disease arising from imbalanced lipid metabolism and a maladaptive immune response. The lymphatic system ensures tissue fluid homeostasis, absorption of dietary fats and trafficking of immune cells to draining lymph nodes, thereby potentially affecting atherogenesis. Endothelial cell-specific deletion of Pannexin1 (Panx1) in apolipoprotein E-deficient (Apoe-/-) mice increased atherosclerosis, suggesting a protective role for Panx1 channels in arterial endothelial function. Here, we investigated the role of Panx1 in lymphatic endothelial cells (LECs) in the initiation and the progression of atherosclerosis. Male or female Prox1-CreERT2+Panx1fl/flApoe-/- and Panx1fl/flApoe-/- mice were fed a high cholesterol diet (HCD) for 6 or 10 weeks. Tamoxifen-induced deletion of Panx1 was performed before or after 4 weeks of HCD. Body weight and serum lipid profiles were determined. The atherosclerotic plaque burden was assessed by Sudan-IV staining on thoracic-abdominal aortas and in aortic roots. Plaque composition was determined by immunohistochemistry. No differences in serum cholesterol, LDL and HDL were observed between genotypes and between sexes after HCD. Bodyweight, serum triglycerides and free fatty acid levels were higher before and after 6 weeks of HCD in male Prox1-CreERT2+Panx1fl/flApoe-/- and control Panx1fl/flApoe-/- mice compared to females of the same genotypes, which was associated with more lipids and inflammatory cells in their atherosclerotic plaques. In contrast, the atherosclerotic plaque burden was higher in female mice. The progression of atherosclerosis in male mice was not different between genotypes. However, female Prox1-CreERT2+Panx1fl/flApoe-/- mice showed enhanced progression of atherosclerosis compared to Panx1fl/flApoe-/- controls of the same sex. In addition, atherosclerotic lesions in female, but not in male, Prox1-CreERT2+Panx1fl/flApoe-/- mice showed T cell enrichment. Altogether, our results reveal differential sex-dependent effects of Panx1 in lymphatic endothelium on the progression of atherosclerosis.

Introduction

The lymphatic vasculature forms an unidirectional transport pathway from the interstitial space to the systemic veins. The lymphatic system comprises a network of blind-ended capillaries, valved collecting vessels, larger ducts and lymph nodes (LNs), which ensures tissue fluid homeostasis, absorption of dietary fats and trafficking of immune cells such as dendritic cells (DCs) to draining LNs [1]. Lymphangiogenesis, the formation of new lymphatic vessels from existing ones, occurs mainly in response to the activation of vascular endothelial growth factor receptor 3 (VEGFR3) by vascular endothelial growth factor C (VEGFC), which stimulates the proliferation of lymphatic endothelial cells (LECs) [2]. LECs are among the principal actors safeguarding the different functions of the lymphatic system [3]. Dysfunctional lymphatic vessels give rise to various pathological conditions, including inherited and acquired forms of lymphedema, malabsorption syndromes, autoimmune disorders and immune deficiencies [4]. Recent evidence points to a role for the lymphatic system in atherosclerosis [5, 6].

Atherosclerosis is the underlying cause of myocardial infarction and stroke and is the world’s leading cause of death [7]. This progressive disease affecting medium-sized and large arteries is characterized by an endothelial dysfunction, accumulation of lipids in the intima and an inflammatory response leading to the formation of atherosclerotic plaques [8]. The progression of the disease implies further recruitment of inflammatory cells, smooth muscle cell (SMC) migration and proliferation, cell death and fibrosis. Together, these factors determine atherosclerotic plaque stability and the risk of plaque rupture leading to acute cardiovascular events [9]. Stable atherosclerotic lesions display a thick fibrous cap with a high content of SMCs, a small necrotic core and a low macrophage content [10].

Both in mice and human, lymphatic vessels are mostly present in the arterial adventitial layer, and arteries with a dense lymphatic network seem naturally protected against atherosclerosis [5, 11]. Two independent atherosclerosis-susceptible mouse models with severe lymphatic insufficiency showed increased serum cholesterol levels and enhanced atherogenesis, pointing to a protective role for lymphatic vessels in maintaining proper lipoprotein and vascular homeostasis [12]. In agreement, dissection of plaque draining LNs and lymphatic vessels in apolipoprotein E-deficient (Apoe-/-) mice worsened atherosclerosis irrespective of serum lipids, with T lymphocyte accumulation in the atherosclerotic plaques and in the adventitia [13]. In addition, inhibition of VEGFR3-mediated signaling caused T cell enrichment in atherosclerotic lesions, without compromising adventitial lymphatic density, suggesting the involvement of VEGFR3-independent growth of lymphatics [13]. Interestingly, the membrane channel-forming protein pannexin1 (Panx1) is highly expressed in human LECs and has been shown to regulate lymphangiogenesis in vitro [14].

Panx1 channels allow for the diffusion of ions and signaling molecules between the cytosol and the extracellular environment [15, 16]. Panx1 channels control the inflammatory response by regulating inflammasome activation and leukocyte migration [15]. We have previously shown that atherosclerosis was enhanced in Tie2-CreTgPanx1fl/flApoe-/- mice, pointing to an atheroprotective role for Panx1 in endothelial and/or monocytic cells. Interestingly, Panx1-/-Apoe-/- mice showed impairment of lymphatic function with reduced dietary fat absorption, which counterbalanced the proatherogenic effect of Tie2-Cre-induced Panx1 deletion from these cells [17].

Taken together, these studies suggest a central role for Panx1 in linking lymphatic function to lipid metabolism and atherogenesis. However, whether specific Panx1 deletion in LECs affects atherosclerotic plaque burden and composition remains yet to be discovered.

Methods

Animals

Animal experimentation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1966) and all experiments were approved by the Swiss cantonal veterinary authorities. All mice were housed in a conventional standard animal facility at 24°C with light cycles of 12 hours of light and 12 hours of night. Cages were enriched with a carton house and cottons. Male and female Prox1CreERT2Panx1fl/flApoe-/- (Panx1LECdelApoe-/-) and Panx1fl/flApoe-/- control mice, on a C57BL/6J background, were used in this study (Fig 1). All mice received twice a day, for 4 consecutive days, intraperitoneal injections of 1 mg tamoxifen (Sigma) in kolliphor oil (Sigma), either before high cholesterol diet (HCD; Fig 1A) or after 4 weeks of HCD (Fig 1B). This protocol is known to induce effective and specific Panx1 deletion from LECs [18]. Submandibular blood sampling was performed under short-term anesthesia with isofluorane inhalation (4%). Mice were fed for a total of 6 or 10 weeks with a HCD (1.25% cholesterol, 0% cholate; Safe diets). Thereafter, mice were killed under general anesthesia induced by an intraperitoneal injection of ketarom (10 mg/kg xylazine mixed with 100 mg/kg ketamine).

Fig 1. Timeline for initiation and progression of atherosclerosis.

Fig 1

(A) For the initiation study, Panx1 deletion was induced at 6 weeks of age by tamoxifen injection for consecutive 4 days. When mice reached 10 weeks of age, blood was taken from female and male Panx1LECdelApoe-/- and control Panx1fl/flApoe-/- mice and they were placed on a HCD for 6 weeks. At 16 weeks of age, mice were killed and blood and different tissues were collected. (B) For the progression study, blood was sampled at 6 weeks of age and atherosclerosis was induced in control Panx1fl/flApoe-/- and Panx1LECdelApoe-/- mice by feeding them with a HCD for 10 weeks. Four weeks after the start of the HCD, Panx1 deletion was induced with tamoxifen injections. At the end of the 10 weeks HCD period, mice were killed and blood and tissues were collected.

Blood and tissue collection

Blood was collected by cardiac puncture and serum was obtained after 15 min centrifugation at 5000 rpm at 4°C. The mice were then perfused with 0.9% NaCl and organs were dissected. Aortic roots were embedded in OCT compound (Tissue-Tek; Sakura) and snap-frozen. Thoracic-abdominal aortas were fixed in 4% paraformaldehyde (PFA) for 24 hours, rinsed with phosphate-buffered saline (PBS), incubated overnight in a Sudan-IV solution and longitudinally opened along the ventral midline, as described previously [19, 20]. The extent of atherosclerosis was determined by dividing Sudan-IV-positive area by the total surface of the thoracic-abdominal aorta. Atherosclerotic plaque burden was also analyzed in 5 serial cryosections of aortic roots (5 μm thickness, inter-distance 50 μm). Images were captured with a Zeiss Axioscan.Z1 automated slide scanner and quantification was performed by computer image analysis using Qpath v0.4.3 software. The extent of atherosclerosis was determined by dividing atherosclerotic area by the total surface of the aortic roots for each cryosection. An average value of all cryosections was calculated for each mouse.

Histological analysis

Immunostaining on cryosections of aortic roots involved different protocols. For macrophages, the staining was performed using CD68 primary antibody (1:1000; Biorad). In brief, after fixation with acetone (5 min), neutralization with 0.5 mol/L NH4Cl (15 min), incubation for 10 min with BLOXALL (Vector Laboratories) and blocking with 2.5% normal horse serum (10 min), sections were incubated with the primary antibody at room temperature (RT) for 90 min. Staining was visualized using a secondary antibody coupled to streptavidin detected with a 3,3′-Diaminobenzidine (DAB) substrate kit (Vector Laboratories). Sections were counterstained with a hemalun Meyer’s solution (Merck) and finally mounted with Aquatex (Sigma). For SMCs, the staining was performed using α-smooth muscle actin antibody (α-SMA; 1:50, kindly provided by M-L Bochaton-Piallat). In brief, after fixation with 4% PFA (15 min) and post-fixation/permeabilization at -20°C with MeOH (3 min), sections were incubated for 1 hour at RT with the primary antibody, which was detected using a goat anti-mouse IgG2a Alexa 488 antibody (1:100; Jackson Laboratories) for 30 min at RT. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI; 1/20000; Invitrogen) for 10 min. Slides were mounted with Vectashield mounting medium (Vector Laboratories). For T lymphocytes, the staining was performed using CD3 primary antibody (1:100; CD3-12; Biorad). In brief, after fixation with PFA (15 min), permeabilization with 0.3% Triton-X100 (15 min), neutralization with 0.5 mol/L NH4Cl (15 min), and blocking with 10% normal goat serum (10 min; Vector Laboratories), sections were overnight incubated with the primary antibody at 4°C. Staining was visualized using a goat anti-rat Alexa488 secondary antibody (1:100; Jackson Laboratories). Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI; 1/20000; Invitrogen) for 10 min. Slides were mounted with Vectashield mounting medium (Vector Laboratories). Collagen was visualized and quantified after Masson’s trichrome staining. Lymphatic vessels were fluorescently stained using a LYVE-1 antibody (1:500; Angiobio). In brief, after fixation with 4% PFA (15 min), permeabilization with 0.2% Triton X-100 during 1 hour and blocking for 30 min with 2% bovine serum albumin, sections were incubated overnight with the primary antibody. Sections were then incubated with an Alexa 568 goat anti-rabbit secondary antibody (1/2000; Jackson Laboratories) at RT for 1 hour. Nuclei were stained with DAPI for 10 min (1/20000; Invitrogen). Slides were mounted with Vectashield mounting medium (Vector Laboratories). All images were captured with an Axio Scan.Z1 (Zeiss) automated slide scanner or an Axiocam-Fluo microscope (Zeiss). Quantification was performed using the Qpath v0.4.3 software. The percentage of positive cells was determined by dividing the positively stained surface by total lesion area, or the number of LYVE+ lymphatic vessels or the number of CD3+ cells in atherosclerotic lesions were counted.

Biochemical analysis of serum

A Cobas C111 analyzer (Roche Diagnostics) was used to measure total cholesterol, LDL, HDL, triglyceride (TG) and free fatty acid (FFA) levels in mouse sera before and after HCD.

Quantitative PCR

LEC extraction and culture was performed using previously described protocols [18, 21]. Briefly, dermal LNs were collected, pooled and incubated in RPMI-1640 medium (Gibco) containing 0.8 mg/mL dispase (Gibco), 0.2 mg/mL collagenase-P (Roche) and 0.1 mg/mL DNase-1 (Roche) for digestion. After centrifugation, extracted cells were filtered through a 70 μm cell strainer and 5 x 106 cells were seeded in 6-well plates coated with 10 μg/mL human fibronectin (Merck) and 10 μg/mL Purecol (Cellsystems). Culture medium (alpha-MEM; Gibco) was renewed every other day. After 7 days cells were detached by incubating them with Accutase (5 min; 37°C; Gibco), LECs were sorted by flow cytometry using previously established protocols [18] and total RNA was extracted using a RNAqueous-Micro Kit (Thermo Fisher) according to the manufacturer’s instructions. cDNA was obtained using the Quantitect Reverse Transcription kit (Qiagen) and real-time PCR was performed with a QuantStudio 6 Pro (Thermo Fisher) using the TaqMan Fast Universal master mix (Applied Biosystem). Mouse vascular cell adhesion molecule 1 (VCAM-1) or 18S primers and probes were obtained from Applied Biosystems.

Statistical analysis

Statistical analyses were performed with Graphpad Prism 9 software and results were reported as mean ± SEM. Two-group comparisons were performed using the Student’s t-test. Multiple groups comparisons were performed using ANOVA with Bonferroni’s post-test. Differences with P≤0.05 were considered as statistically significant.

Results

Panx1 deficiency in LECs does not affect the number of adventitial lymphatic vessels

To investigate a potential contribution of Panx1 in LECs in the initiation of atherosclerosis, we induced Panx1 deletion with tamoxifen in 6 weeks-old Panx1LECdelApoe-/- mice and control Panx1fl/flApoe-/- mice. Four weeks later, when mice reached 10 weeks of age, we induced atherosclerosis by feeding the mice with a HCD for 6 weeks (Fig 1A). To determine whether Panx1 deletion from LECs would affect the number of lymphatic vessels in atherosclerotic lesions, we performed LYVE-1 immunofluorescent staining on aortic roots of both male and female Panx1LECdelApoe-/- and control Panx1fl/flApoe-/- mice. Lymphatic vessels (stained in red) were typically found in the adventitial layer of the aorta, beneath the atherosclerotic lesions (Fig 2A). Neither Panx1 deletion in LECs nor the sex of the mice did affect the number of lymphatic vessels at this location (Fig 2B). These results confirm the presence of lymphatic vessels in the adventitia of the aorta at the level of the aortic valves, our principal study location. Moreover, they demonstrate that Panx1 deletion or that the sex of the mice did not affect the amount of lymphatic vessels present during the early phases of atherosclerotic plaque development.

Fig 2. Adventitial lymphatic vessel number is similar in male and female Panx1LECdelApoe-/- and control mice.

Fig 2

(A) Representative images of LYVE1 immunofluorescent staining (red) in aortic roots. Nuclei were stained with DAPI (blue). Scale bar represents 50 μm. (B) The lymphatic vessel number in the aortic roots was counted in female control Panx1fl/flApoe-/- mice (white), female Panx1LECdelApoe-/- mice (grey), male control Panx1fl/flApoe-/- mice (light blue) and male Panx1LECdelApoe-/- mice (dark blue). Mean ± SEM, N = 9–10.

Male mice have higher levels of serum triglycerides and free fatty acids

Body weight and serum lipid levels were measured before and after HCD (Fig 1A). As expected, male mice were heavier than female mice irrespective of their genotype. All mice significantly increased their weight during HCD, but no differences in weight gain were observed between males and females nor between Panx1fl/flApoe-/- and Panx1LECdelApoe-/- mice (Fig 3A). In addition, all mice showed an increase in total serum cholesterol, LDL and HDL, irrespective of their genotype or sex (Fig 3B–3D). However, we observed higher levels of serum TG and FFA before and after HCD in male Panx1LECdelApoe-/- and control Panx1fl/flApoe-/- mice compared to females of the same genotypes (Fig 3E and 3F). These results point to sex-dependent differences in lipid metabolism between male and female mice under HCD during the initiation of atherosclerosis.

Fig 3. Males have higher serum levels of TG and FFA after 6 weeks of HCD.

Fig 3

Body weight (A), serum cholesterol (B), LDL (C), HDL (D), TG (E) and FFA (F) levels of female control Panx1fl/flApoe-/- mice (white), female Panx1LECdelApoe-/- mice (grey), male control Panx1fl/flApoe-/- mice (light blue) and male Panx1LECdelApoe-/- mice (dark blue) before and after 6 weeks of HCD. Mean ± SEM, N = 8–10, **P≤0.01, ***P≤0.001, ****P≤0.0001.

Female mice develop larger atherosclerotic plaques

Next, we assessed whether Panx1 deletion in LECs affects the atherosclerotic burden in female and male Panx1LECdelApoe-/- and Panx1fl/flApoe-/- mice after 6 weeks of HCD. To this end, Sudan-IV staining was performed on cryosections of aortic roots and on longitudinally opened thoraco-abdominal aortas of all mice (Fig 4A). In both Panx1LECdelApoe-/- and control Panx1fl/flApoe-/- mice, we found larger atherosclerotic lesions in aortic roots from female mice compared to male mice of the same genotype (Fig 4B). However, the atherosclerotic burden was not different in thoracic-abdominal aortas from male and female mice of both genotypes (Fig 4C). As atherosclerotic lesions develop earlier at the level of the aortic roots [22], potential differences in atherosclerotic burden can be quicker detected at this location. These observations point to a promoting effect of female sex on early atherosclerotic plaque burden and this seems independent of serum lipid levels.

Fig 4. Females have larger atherosclerotic plaques in aortic roots after 6 weeks of HCD.

Fig 4

Sudan-IV staining (A) and quantification of atherosclerotic plaque burden in aortic roots (B) and thoraco-abdominal aortas (C) of female control Panx1fl/flApoe-/- mice (white), female Panx1LECdelApoe-/- mice (grey), male control Panx1fl/flApoe-/- mice (light blue) and male Panx1LECdelApoe-/- mice (dark blue) after 6 weeks of HCD. Scale bar represents 200 μm. Mean ± SEM, N = 9–10, *P≤0.05.

Atherosclerotic plaque vulnerability is increased in male mice

Atherosclerotic plaque rupture can occur due to a decline in its mechanical stability. Histopathological analysis of atherosclerotic lesions associated with fatal myocardial infarction revealed a substantial lipid core, a thin fibrous cap, an accumulation of activated macrophages producing matrix metalloproteinases and a reduction in SMCs responsible for synthesizing extracellular matrix [23]. We evaluated whether Panx1 in LECs affects the phenotype of atherosclerotic lesions by analyzing the plaque composition in Panx1LECdelApoe-/- and control Panx1fl/flApoe-/- mice after 6 weeks of HCD. No differences were found in the amount of the plaque stabilizing factors, collagen (in blue; Fig 5A and 5B) and SMCs (in green; Fig 5C and 5D), between mice of both sexes and genotypes. Interestingly, we observed differences in the amount of the plaque destabilizing factors, lipids (in red; Fig 5E and 5F) and CD68+ macrophages (in brown; Fig 5G and 5H), i.e. the area covered by lipids and inflammatory cells was increased in male mice compared to female mice and this was independent of the genotype. Thus, male mice have more vulnerable plaques characterized by an increased content of destabilizing factors.

Fig 5. Reduced atherosclerotic plaque stability in male mice after 6 weeks of HCD.

Fig 5

Representative images and quantification of (immuno-) stainings for collagen (A,B; in blue), α-SMA (C,D; in green), Sudan-IV (E,F; in red) and CD68 (G,H; in brown) performed on aortic roots of female control Panx1fl/flApoe-/- mice (white), female Panx1LECdelApoe-/- mice (grey), male control Panx1fl/flApoe-/- mice (light blue) and male Panx1LECdelApoe-/- mice (dark blue) after 6 weeks of HCD. Scale bars represent 100 μm for A and E, and 200 μm for C and G. Mean ± SEM, N = 9–10, **P≤0.01, ***P≤0.001, ****P≤0.0001.

In summary, LEC-specific deletion of Panx1 did not alter body weight, serum lipid levels, atherosclerotic plaque burden and composition during early atherosclerosis. However, male mice had increased serum levels of TG and FFA, with or without HCD, which may have contributed to an increased lipid content in their atherosclerotic plaques attracting more macrophages and leading to a more vulnerable lesion phenotype. On the other hand, the early atherosclerotic plaque burden was higher in female mice.

Role of Panx1 in LECs in the progression of atherosclerosis

To investigate a potential contribution of Panx1 in LECs in the progression of atherosclerosis, we placed the mice on a HCD for 4 weeks to initiate the disease, then deleted Panx1 channels in LECs and studied the advanced atherosclerotic plaque burden in the aortic roots after 6 more weeks of HCD (Fig 1B). As expected, the atherosclerosis burden in the aortic roots was increased for all 4 groups after 10 weeks of HCD (Fig 6A and 6B) compared with 6 weeks of HCD (Fig 4C). Moreover, the extent of atherosclerosis after 10 weeks of HCD was higher in female Panx1LECdelApoe-/- mice than in males of the same genotype. This difference was not observed in Panx1fl/flApoe-/- mice and seemed thus to result rather from LEC-specific Panx1 deletion than from sex-dependent differences in advanced atherosclerosis (Fig 6B). Thus, while the early atherosclerotic plaque burden was higher in female mice, this difference was no longer present when plaques advanced. Finally, as the effects of Panx1 deletion on lymphatic function are known to be more subtle than the sizeable effects of sex on cardiovascular disease, we analyzed results onto the effects of LEC-specific Panx1 deletion on the progression of atherosclerosis separately for male and female mice.

Fig 6. Increased advanced atherosclerotic plaque burden in female Panx1LECdelApoe-/- mice.

Fig 6

Sudan-IV staining (A) and quantification of atherosclerotic lesion extent in the aortic roots (B) of female control Panx1fl/flApoe-/- mice (white), female Panx1LECdelApoe-/- mice (grey), male control Panx1fl/flApoe-/- mice (light blue) and male Panx1LECdelApoe-/- mice (dark blue) after 10 weeks of HCD. Scale bar represents 200 μm. Mean ± SEM, N = 8–9, **P≤0.01.

The body weight (Fig 7A), serum cholesterol (Fig 7B) and LDL (Fig 7C) levels were similarly increased in male Panx1LECdelApoe-/- and Panx1fl/flApoe-/- mice after 10 weeks of HCD. Likewise, we did not observe any difference in serum HDL (Fig 7D), TG (Fig 7E) and FFA (Fig 7F) levels between male Panx1LECdelApoe-/- and control Panx1fl/flApoe-/- mice after the 10 weeks of HCD. This implies that inducing Panx1 deletion in LECs did not affect circulating lipid concentrations during the progression of atherosclerosis.

Fig 7. Panx1 deletion in LECs does not affect serum lipid levels and advanced atherosclerotic plaque burden in males.

Fig 7

Body weight (A), serum cholesterol (B), LDL (C), HDL (D), TG (E) and FFA (F) levels of male control Panx1fl/flApoe-/- mice (light blue) and male Panx1LECdelApoe-/- mice (dark blue) after 10 weeks of HCD. Sudan-IV staining (E) and quantification of atherosclerotic lesion burden in thoraco-abdominal aortas (F) of male Panx1fl/flApoe-/- mice (light blue) and male Panx1LECdelApoe-/- mice (dark blue) after 10 weeks of HCD. Mean ± SEM, N = 9, *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001.

Next, we analyzed the atherosclerotic plaque burden in the thoracic-abdominal aortas in male Panx1fl/flApoe-/- and Panx1LECdelApoe-/- mice after 10 weeks of HCD. Similar to the observations during early atherosclerosis (Fig 4), we found no effect of LEC-specific Panx1 deletion on lesion burden in the thoracic-abdominal aortas (Fig 7G and 7H) nor in the aortic roots (Fig 6B) of the mice after 10 weeks of HCD. This suggests that Panx1 in LECs does not play a substantial role in modulating the initiation and the progression of atherosclerotic lesions in male mice.

Finally, we investigated whether Panx1 deletion in LECs during plaque development may affect the composition of advanced atherosclerotic plaques in male Panx1LECdelApoe-/- mice. Panx1 deletion had no impact on the phenotype of the lesions in male mice, neither for the stabilizing factors such as collagen (Fig 8A) and SMCs (Fig 8B) nor for the destabilizing factors like lipids (Fig 8C) and CD68+ macrophages (Fig 8D). The number of T lymphocytes in the advanced atherosclerotic lesions was also not different between Panx1LECdelApoe-/- and control Panx1fl/flApoe-/- mice (Fig 8E). Despite the sex-specific favorable early plaque phenotype in male mice, the deletion of Panx1 from LECs during atherosclerotic plaque progression had no effect on the stability of atherosclerotic lesions in male mice.

Fig 8. Panx1 deletion in LECs does not affect advanced plaque stability in males.

Fig 8

Quantification of (immuno-)stainings for collagen (A), α-SMA (B), Sudan-IV (C), CD68 (D) and CD3 (E) in aortic roots of male Panx1fl/flApoe-/- mice (light blue) and male Panx1LECdelApoe-/- mice (dark blue) after 10 weeks of HCD. Mean ± SEM, N = 9.

To investigate if deletion of Panx1 channels in LECs affects the progression of atherosclerosis in female mice, we used the same protocol as for the male mice (Fig 1B). Female Panx1LECdelApoe-/- and control Panx1fl/flApoe-/- mice had a similar body weight before the HCD and their weight gain after the 10 weeks of HCD was not different (Fig 9A). Likewise, the serum cholesterol levels of female Panx1LECdelApoe-/- and Panx1fl/flApoe-/- mice were not different before the HCD and they showed a similar increase following the 10 weeks of HCD (Fig 9B). Along the same line, serum LDL (Fig 9C), HDL (Fig 9D), TG (Fig 9E) and FFA (Fig 9F) levels did not differ between the two genotypes before and after HCD. Similar to the results obtained in male mice, inducing Panx1 deletion in LECs did not affect the serum lipids in female mice during the progression of atherosclerosis.

Fig 9. Panx1 deletion in LECs enhances advanced atherosclerosis in aortic roots of female mice.

Fig 9

Body weight (A), serum cholesterol (B), LDL (C), HDL (D), TG (E) and FFA (F) levels of female control Panx1fl/flApoe-/- mice (white) and female Panx1LECdelApoe-/- mice (grey) after 10 weeks of HCD. Sudan-IV staining (E) and quantification of atherosclerotic lesion burden in thoraco-abdominal aortas (F) of male Panx1fl/flApoe-/- mice (white) and male Panx1LECdelApoe-/- mice (grey) after 10 weeks of HCD. Mean ± SEM, N = 8–9, *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001.

The extent of the atherosclerotic lesions tended to be increased in female Panx1LECdelApoe-/- mice compared to Panx1fl/flApoe-/- control mice at the level of the aortic roots (Fig 6B) and we observed a similar trend towards increased plaque burden in the thoracic-abdominal aortas of female Panx1LECdelApoe-/- mice (Fig 9G and 9H). These results suggest an atheroprotective role for Panx1 in LECs in female mice during the progression of atherosclerosis.

Finally, we examined whether Panx1 deletion in LECs during plaque development affects the composition of advanced atherosclerotic plaques in female Panx1LECdelApoe-/- and Panx1fl/flApoe-/- mice. We did not observe genotype-dependent differences in female mice with respect to the plaque stabilizing collagen and SMC content (Fig 10A and 10B) and the plaque destabilizing lipid and macrophage content (Fig 10C and 10D) in advanced atherosclerotic plaques. However, the number of T lymphocytes in the advanced atherosclerotic lesions was increased in female Panx1LECdelApoe-/- mice as compared to control Panx1fl/flApoe-/- mice of the same sex (Fig 10E). Interestingly, the expression level of VCAM-1 was lower in Panx1-deficient LECs than in Panx1-expressing LECs isolated from LNs of female mice (Fig 10F). In summary, female Panx1LECdelApoe-/- mice tend to have more atherosclerotic lesions that contained more T lymphocytes than the plaques of control Panx1fl/flApoe-/- mice.

Fig 10. Panx1 deletion in LECs results in T cell enrichment in advanced atherosclerotic lesions of female mice.

Fig 10

Quantification of (immuno-)stainings for collagen (A), α-SMA (B), Sudan-IV (C), CD68 (D) and CD3 (E) in aortic roots of female Panx1fl/flApoe-/- mice (white) and female Panx1LECdelApoe-/- mice (grey) after 10 weeks of HCD. Mean ± SEM, N = 8–9. VCAM-1 expression (F) in Panx1-expressing (white) and Panx1-deficient (grey) LECs isolated from LNs of female mice. Mean ± SEM, n = 4. *P≤0.05, **P≤0.01.

Discussion

Panx1 expression is higher in LECs of male mice than in the ones of female mice [18]. Panx1 deletion in LECs is known to alter important lymphatic functions such as tissue fluid drainage, dietary fat uptake and DC migration to draining LNs in a sex-specific manner [18]. The present study was undertaken to study the effects of Panx1 deletion in LECs on the initiation and the progression of atherosclerosis in male and female mice.

Lymphatic vessels are typically found in the adventitial layer beneath atherosclerotic plaques and close to the vasa vasorum [24], which was also the case in our study (Fig 2). Panx1 deletion in LECs did not affect the number of adventitial lymphatic vessels both in male and in female mice. Although an earlier study showed that Panx1 regulated lymphangiogenesis in vitro [14], our results did not confirm these results in vivo, suggesting a minor or no role of LEC Panx1 in lymphangiogenesis in atherosclerotic lesions. The relation between Panx1 in LECs and atherosclerosis may however go beyond quantitative changes in lymphatic vessel number and further experiments focused on the implications of LEC-specific Panx1 deletion on atherosclerotic plaque burden and stability during the initiation phase as well as during the progression of the disease.

During early atherosclerosis induced by 6 weeks of HCD, we observed mainly sex-dependent differences rather than differences induced by Panx1 gene deletion. As expected, the body weight was higher in males than in females (Fig 3A) [25]. Both males and females increased their serum cholesterol, LDL and HDL levels to a similar extent in response to the HCD (Fig 3B and 3D). However, serum TG and FFA levels were higher in male Panx1fl/flApoe-/- and Panx1LECdelApoe-/- mice compared to females (Fig 3E and 3F), which points to a potential role of sex hormones in lipid metabolism. This may be linked to sex-dependent differences in clearance of TG and fat storage. It has been shown that estradiol promotes the accumulation of subcutaneous fat and that estrogen deficiency in women leads to weight gain [26]. Moreover, another study revealed that women produce more TG-rich very low-density lipoproteins (VLDL), which are matched by higher rates of lipoprotein lipase-mediated VLDL clearance, causing an overall lower blood TG level in women [27]. The difference in dietary lipid processing between male and female mice may also result from sex-dependent changes in the trafficking of dietary fats through lymphatic vessels. Using a well-established lymphatic fistula model, it has been shown that female mice displayed a lower lymphatic flow of triacylglycerol than male mice [28]. Further to the differences in serum TG and FFA levels, we found that female mice had an increased early atherosclerotic burden in the aortic roots compared to males (Fig 4B), but the male plaques were more vulnerable due to increased content of macrophages and lipids (Fig 5E–5H). This is in accordance with a previous study in which male Apoe-/- mice showed smaller atherosclerotic plaques in the aortic roots, but expressed higher levels of pro-inflammatory macrophage markers than females [29]. Moreover, it illustrates that the size of a lesion does not necessarily correlate with its vulnerability (i.e. probability to rupture), corroborating an observation that is long known from clinical studies [30]. It also highlights that in mouse models of atherosclerosis, the plaque inflammatory status rather than the plaque size may be closer to sex-specific clinical outcomes found in humans due to its contribution to plaque vulnerability [29].

Limiting plaque progression, or even inducing plaque regression, may involve a reduction in plaque lipid content, macrophage and T cell content and inflammatory status [31], which are all processes in which the lymphatic system has a regulatory function. In an attempt to mimic as closely as possible a potential clinical treatment situation involving Panx1 channels, we used a study protocol in which atherosclerosis was initiated by 4 weeks of HCD, and Panx1 channels were subsequently deleted from the lymphatic endothelium while the HCD continued for another 6 weeks. As the male early atherosclerotic plaques appeared more vulnerable than female plaques (Fig 5), we first examined the impact of Panx1 deletion in LECs in male mice. We observed no differences between the male Panx1LECdelApoe-/- and control Panx1fl/flApoe-/- mice in terms of serum lipid levels (Fig 7), atherosclerotic plaque burden after 10 weeks of HCD (Figs 6 and 7) or advanced plaque stability (Fig 8). These results led us to consider the possibility that a compensatory mechanism may be in place to overcome the effects of Panx1 deficiency in LECs during the progression of the pathology. We checked for the expression of the other members of the pannexin family, Panx2 and Panx3, and did not detect these mRNAs in LECs (data not shown). A hypothetical compensatory mechanism could also involve connexins (Cxs), a family of channel-forming proteins involved in direct cell-to-cell communication [32]. Cxs form hexamers, called connexons, and gap junction channels are formed by the docking of connexons from two adjacent cells. Similar to Panx1 channels, however, connexons can also function as hemichannels allowing the diffusion of small molecules and ions between the cytoplasm and the extracellular environment [33]. Among the Cx family members, Cx47 has been associated to lymphedema [3436] and it is known to be expressed in LECs [3739]. Moreover, Cx47 was shown to regulate serum lipid levels, thereby not altering the atherosclerotic burden but rather plaque composition [39]. Further experiments might elucidate a possible compensatory role of Cx47 in the context of Panx1 deletion and atherosclerosis. Such experiments are however beyond the scope of this study.

In contrast to male mice, female Panx1LECdelApoe-/- mice showed a tendency to a larger atherosclerotic plaque burden after 10 weeks of HCD than control Panx1fl/flApoe-/- mice (Figs 6 and 9G and 9H), despite similar serum lipid levels in both genotypes (Fig 9B–9F). Adventitial lymphatic vessels beneath advanced atherosclerotic lesions drain interstitial fluid and immune cells, particularly T cells and dendritic cells, from the vessel wall to draining lymph nodes [13]. Dysfunction or insufficient number of adventitial lymphatic vessels can exacerbate atherosclerotic plaque progression by preventing proper immune cell clearance and fostering persistent inflammation. Although the number of lymphatic vessels beneath advanced atherosclerotic lesions was similar for both genotypes and sexes (Fig 2), atherosclerotic plaques of female Panx1LECdelApoe-/- mice, but not of male Panx1LECdelApoe-/- mice, contained more T lymphocytes than control Panx1fl/flApoe-/- mice (Figs 8E and 10E). This suggests impaired T cells drainage from female atherosclerotic plaques by lymphatic vessels lacking Panx1 expression in LECs. In agreement, we found a reduced expression of VCAM-1 in female Panx1-deficient LECs compared to female Panx1-expressing LECs (Fig 10F), further supporting the hypothesis of a sex-specific regulation of T cell drainage by Panx1 expression in LECs. However, whether the sex-specific decrease in T cell drainage results in the increased atherosclerotic plaque burden in female Panx1LECdel mice still remains to be proven.

In conclusion, while Panx1 deletion did not influence the early stages of atherosclerosis, it emerged as a factor in modulating disease progression in females. Independent of Panx1 expression, a sex-specific difference in early atherogenesis was also found in this study with a larger atherosclerotic plaque burden in female compared to the male mice. Together these observations suggest that lymphatic Panx1 exerts a protective effect against atherosclerosis progression in female mice, highlighting the complex interplay between sex-specific factors and disease pathogenesis.

Acknowledgments

We thank Viviane Bes for excellent technical assistance and advice.

Data Availability

The source data that support the findings will be available in YARETA following acceptance of the manuscript.

Funding Statement

This study was supported by grants from the Swiss National Science Foundation (grant number 310030_182573 to BRK) and the Gabbiani fund (to AE). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Breslin JW, Yang Y, Scallan JP, Sweat RS, Adderley SP, Murfee WL. Lymphatic Vessel Network Structure and Physiology. Compr Physiol. 2018;9(1):207–99. doi: 10.1002/cphy.c180015 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Karaman S, Leppanen VM, Alitalo K. Vascular endothelial growth factor signaling in development and disease. Development. 2018;145(14). doi: 10.1242/dev.151019 . [DOI] [PubMed] [Google Scholar]
  • 3.Zhang F, Zarkada G, Yi S, Eichmann A. Lymphatic Endothelial Cell Junctions: Molecular Regulation in Physiology and Diseases. Front Physiol. 2020;11:509. doi: 10.3389/fphys.2020.00509 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Csanyi G, Singla B. Arterial Lymphatics in Atherosclerosis: Old Questions, New Insights, and Remaining Challenges. J Clin Med. 2019;8(4). doi: 10.3390/jcm8040495 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Kutkut I, Meens MJ, McKee TA, Bochaton-Piallat ML, Kwak BR. Lymphatic vessels: an emerging actor in atherosclerotic plaque development. Eur J Clin Invest. 2015;45(1):100–8. doi: 10.1111/eci.12372 . [DOI] [PubMed] [Google Scholar]
  • 6.Davis MJ, Scallan JP, Castorena-Gonzalez JA, Kim HJ, Ying LH, Pin YK, et al. Multiple aspects of lymphatic dysfunction in an ApoE (-/-) mouse model of hypercholesterolemia. Front Physiol. 2022;13:1098408. doi: 10.3389/fphys.2022.1098408 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Brusca SB, Albert MA. Balancing the scales of adversity: a socioecological approach to reducing the global burden of stroke and cardiovascular disease. Lancet Neurol. 2023;22(12):1094–6. doi: 10.1016/S1474-4422(23)00386-1 . [DOI] [PubMed] [Google Scholar]
  • 8.Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56. doi: 10.1038/s41572-019-0106-z . [DOI] [PubMed] [Google Scholar]
  • 9.Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524–33. doi: 10.1038/s41586-021-03392-8 . [DOI] [PubMed] [Google Scholar]
  • 10.Sarraju A, Nissen SE. Atherosclerotic plaque stabilization and regression: a review of clinical evidence. Nat Rev Cardiol. 2024. doi: 10.1038/s41569-023-00979-8 . [DOI] [PubMed] [Google Scholar]
  • 11.Drozdz K, Janczak D, Dziegiel P, Podhorska M, Patrzalek D, Ziolkowski P, et al. Adventitial lymphatics of internal carotid artery in healthy and atherosclerotic vessels. Folia Histochem Cytobiol. 2008;46(4):433–6. doi: 10.2478/v10042-008-0083-7 . [DOI] [PubMed] [Google Scholar]
  • 12.Vuorio T, Nurmi H, Moulton K, Kurkipuro J, Robciuc MR, Ohman M, et al. Lymphatic vessel insufficiency in hypercholesterolemic mice alters lipoprotein levels and promotes atherogenesis. Arterioscler Thromb Vasc Biol. 2014;34(6):1162–70. doi: 10.1161/ATVBAHA.114.302528 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Rademakers T, van der Vorst EP, Daissormont IT, Otten JJ, Theodorou K, Theelen TL, et al. Adventitial lymphatic capillary expansion impacts on plaque T cell accumulation in atherosclerosis. Sci Rep. 2017;7:45263. doi: 10.1038/srep45263 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Boucher J, Simonneau C, Denet G, Clarhaut J, Balandre AC, Mesnil M, et al. Pannexin-1 in Human Lymphatic Endothelial Cells Regulates Lymphangiogenesis. Int J Mol Sci. 2018;19(6). doi: 10.3390/ijms19061558 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Rusiecka OM, Tournier M, Molica F, Kwak BR. Pannexin1 channels-a potential therapeutic target in inflammation. Front Cell Dev Biol. 2022;10:1020826. doi: 10.3389/fcell.2022.1020826 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Koval M, Cwiek A, Carr T, Good ME, Lohman AW, Isakson BE. Pannexin 1 as a driver of inflammation and ischemia-reperfusion injury. Purinergic Signal. 2021;17(4):521–31. doi: 10.1007/s11302-021-09804-8 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Molica F, Meens MJ, Dubrot J, Ehrlich A, Roth CL, Morel S, et al. Pannexin1 links lymphatic function to lipid metabolism and atherosclerosis. Sci Rep. 2017;7(1):13706. doi: 10.1038/s41598-017-14130-4 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ehrlich A, Pelli G, Pick R, Clochard L, Molica F, Kwak BR. Pannexin1 deletion in lymphatic endothelium affects lymphatic function in a sex-dependent manner. Physiol Rep. 2024;12(15):e16170. doi: 10.14814/phy2.16170 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kwak BR, Veillard N, Pelli G, Mulhaupt F, James RW, Chanson M, et al. Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Circulation. 2003;107(7):1033–9. doi: 10.1161/01.cir.0000051364.70064.d1 . [DOI] [PubMed] [Google Scholar]
  • 20.Wong CW, Christen T, Roth I, Chadjichristos CE, Derouette JP, Foglia BF, et al. Connexin37 protects against atherosclerosis by regulating monocyte adhesion. Nat Med. 2006;12(8):950–4. doi: 10.1038/nm1441 . [DOI] [PubMed] [Google Scholar]
  • 21.Garnier L, Pick R, Montorfani J, Sun M, Brighouse D, Liaudet N, et al. IFN-gamma-dependent tumor-antigen cross-presentation by lymphatic endothelial cells promotes their killing by T cells and inhibits metastasis. Sci Adv. 2022;8(23):eabl5162. doi: 10.1126/sciadv.abl5162 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Chadjichristos CE, Scheckenbach KE, van Veen TA, Richani Sarieddine MZ, de Wit C, Yang Z, et al. Endothelial-specific deletion of connexin40 promotes atherosclerosis by increasing CD73-dependent leukocyte adhesion. Circulation. 2010;121(1):123–31. doi: 10.1161/CIRCULATIONAHA.109.867176 . [DOI] [PubMed] [Google Scholar]
  • 23.Farb A, Kolodgie FD, Hwang JY, Burke AP, Tefera K, Weber DK, et al. Extracellular matrix changes in stented human coronary arteries. Circulation. 2004;110(8):940–7. doi: 10.1161/01.CIR.0000139337.56084.30 . [DOI] [PubMed] [Google Scholar]
  • 24.Singla B, Aithbathula RV, Pervaiz N, Kathuria I, Swanson M, Ekuban FA, et al. CD47 Activation by Thrombospondin-1 in Lymphatic Endothelial Cells Suppresses Lymphangiogenesis and Promotes Atherosclerosis. Arterioscler Thromb Vasc Biol. 2023;43(7):1234–50. doi: 10.1161/ATVBAHA.122.318904 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Ruff JS, Cornwall DH, Morrison LC, Cauceglia JW, Nelson AC, Gaukler SM, et al. Sexual selection constrains the body mass of male but not female mice. Ecol Evol. 2017;7(4):1271–5. doi: 10.1002/ece3.2753 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Power ML, Schulkin J. Sex differences in fat storage, fat metabolism, and the health risks from obesity: possible evolutionary origins. Br J Nutr. 2008;99(5):931–40. doi: 10.1017/S0007114507853347 . [DOI] [PubMed] [Google Scholar]
  • 27.Palmisano BT, Zhu L, Eckel RH, Stafford JM. Sex differences in lipid and lipoprotein metabolism. Mol Metab. 2018;15:45–55. doi: 10.1016/j.molmet.2018.05.008 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Liu M, Shen L, Yang Q, Nauli AM, Bingamon M, Wang DQ, et al. Sexual dimorphism in intestinal absorption and lymphatic transport of dietary lipids. J Physiol. 2021;599(22):5015–30. doi: 10.1113/JP281621 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Man JJ, Beckman JA, Jaffe IZ. Sex as a Biological Variable in Atherosclerosis. Circ Res. 2020;126(9):1297–319. doi: 10.1161/CIRCRESAHA.120.315930 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92(3):657–71. doi: 10.1161/01.cir.92.3.657 . [DOI] [PubMed] [Google Scholar]
  • 31.Dawson LP, Lum M, Nerleker N, Nicholls SJ, Layland J. Coronary Atherosclerotic Plaque Regression: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(1):66–82. doi: 10.1016/j.jacc.2021.10.035 . [DOI] [PubMed] [Google Scholar]
  • 32.Lucaciu SA, Leighton SE, Hauser A, Yee R, Laird DW. Diversity in connexin biology. J Biol Chem. 2023;299(11):105263. doi: 10.1016/j.jbc.2023.105263 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Ehrlich A, Molica F, Hautefort A, Kwak BR. Lymphatic Connexins and Pannexins in Health and Disease. Int J Mol Sci. 2021;22(11). doi: 10.3390/ijms22115734 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Ferrell RE, Baty CJ, Kimak MA, Karlsson JM, Lawrence EC, Franke-Snyder M, et al. GJC2 missense mutations cause human lymphedema. Am J Hum Genet. 2010;86(6):943–8. doi: 10.1016/j.ajhg.2010.04.010 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Michelini S, Vettori A, Maltese PE, Cardone M, Bruson A, Fiorentino A, et al. Genetic Screening in a Large Cohort of Italian Patients Affected by Primary Lymphedema Using a Next Generation Sequencing (NGS) Approach. Lymphology. 2016;49(2):57–72. . [PubMed] [Google Scholar]
  • 36.Ostergaard P, Simpson MA, Brice G, Mansour S, Connell FC, Onoufriadis A, et al. Rapid identification of mutations in GJC2 in primary lymphoedema using whole exome sequencing combined with linkage analysis with delineation of the phenotype. J Med Genet. 2011;48(4):251–5. doi: 10.1136/jmg.2010.085563 . [DOI] [PubMed] [Google Scholar]
  • 37.Jablon KL, Akerstrom VL, Li M, Braun SE, Norton CE, Castorena-Gonzalez JA. Isolation and short-term culturing of primary lymphatic endothelial cells from collecting lymphatics: A techniques study. Microcirculation. 2023;30(2–3):e12778. doi: 10.1111/micc.12778 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Kanady JD, Dellinger MT, Munger SJ, Witte MH, Simon AM. Connexin37 and Connexin43 deficiencies in mice disrupt lymphatic valve development and result in lymphatic disorders including lymphedema and chylothorax. Dev Biol. 2011;354(2):253–66. doi: 10.1016/j.ydbio.2011.04.004 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Meens MJ, Kutkut I, Rochemont V, Dubrot J, Kaladji FR, Sabine A, et al. Cx47 fine-tunes the handling of serum lipids but is dispensable for lymphatic vascular function. PLoS One. 2017;12(7):e0181476. doi: 10.1371/journal.pone.0181476 . [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Michael Bader

4 Oct 2024

PONE-D-24-40523Atheroprotective role of Panx1 deletion in lymphatic endothelial cells in female micePLOS ONE

Dear Dr. Kwak,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 18 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Michael Bader

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?

2. To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information regarding the experiments involving animals and ensure you have included details on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, and (3) efforts to alleviate suffering.

3. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process.

4. Thank you for stating the following financial disclosure: 

 This study was supported by grants from the Swiss National Science Foundation (grant number 310030_182573 to BRK) and the Gabbiani fund (to AE).  

Please state what role the funders took in the study.  If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."" 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

5. Thank you for stating the following in your Competing Interests section:  

NO authors have competing interests. 

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state ""The authors have declared that no competing interests exist."", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now 

 This information should be included in your cover letter; we will change the online submission form on your behalf.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors investigated the function of Panx1 in lymphatic endothelial cells concerning atherosclerotic lesions and revealed that this molecule specifically regulates lesions in female mice. They concluded that this phenomenon is due to changes in the ability of lymphatic endothelial cells to transport T cells. The results are clear, without significant contradictions, and the novelty is evident, but there appears to be a lack of experimental data regarding immune cells to support the above conclusions. Specifically, the possibility that lymphatic endothelial cells induce qualitative and quantitative changes in immune cells has been overlooked.

Comments

The authors conclude that the promotion of atherosclerosis in female Prox1-CreERT2+Panx1 fl/flApoe-/- mice affects T cell accumulation in the lesions, yet this study does not assess T cell accumulation in the lesions or the populations of T cells in the blood. Since T cells are roughly classified into proinflammatory and anti-inflammatory subsets, both quantitative and qualitative evaluations are essential. Previous reports (PMID: 36519468) have indicated that dysfunction of lymphatic endothelial cells reduces the stability of anti-inflammatory regulatory T cells systemically, increasing susceptibility to atherosclerosis, suggesting that impaired cellular transport via lymphatics may not always be the primary cause. In the author’s context, evaluating lymphatic endothelial cell functions, such as adhesion molecules, is warranted.

The authors should discuss why the observed sex differences occur, in terms of Panx1. The current draft provides extensive explanations regarding gender differences in dyslipidemia; however, as these do not lead to a definitive conclusion, they should be condensed. Instead, the discussion should focus on why there are gender differences in Panx1's contribution to atherosclerosis. It would be beneficial to examine the differences in Panx1 expression between males and females.

Lipoprotein cholesterol and triglycerides should be fractionated into at least VLDL, LDL, and HDL for evaluation. Merely assessing changes in total cholesterol is insufficient to rule out the involvement of dyslipidemia.

The two experimental strategies (initiation and progression) are not clearly linked to the figures, even in the legends. Please revise this for clarity.

Reviewer #2: The goal of this manuscript is to examine the impact of lymphatic endothelial Pannexin 1 (LEC Panx1) on the development and stability of atherosclerotic plaques. Despite being an intriguing subject, the data provided does not indicate a role for LEC Panx1 in atherosclerosis. New findings reveal variations in serum lipid levels, plaque size, and plaque vulnerability based on sex. However, these differences are not linked to the presence or absence of Panx1. Given the data presented, the significance of the results remains uncertain.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Takuro Miyazaki

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Dec 30;19(12):e0315511. doi: 10.1371/journal.pone.0315511.r002

Author response to Decision Letter 0


18 Nov 2024

Reviewer 1

We thank the Reviewer for his/her critical comments that helped us to improve our manuscript. We are happy to note that the Reviewer considers our results as clear without contradictions and that the novelty of our study was evident. We have responded to each of his/her remarks in detail below.

Specific comments:

1) The authors conclude that the promotion of atherosclerosis in female Prox1-CreERT2+Panx1 fl/flApoe-/- mice affects T cell accumulation in the lesions, yet this study does not assess T cell accumulation in the lesions or the populations of T cells in the blood. Since T cells are roughly classified into proinflammatory and anti-inflammatory subsets, both quantitative and qualitative evaluations are essential. Previous reports (PMID: 36519468) have indicated that dysfunction of lymphatic endothelial cells reduces the stability of anti-inflammatory regulatory T cells systemically, increasing susceptibility to atherosclerosis, suggesting that impaired cellular transport via lymphatics may not always be the primary cause. In the author’s context, evaluating lymphatic endothelial cell functions, such as adhesion molecules, is warranted.

Response: We thank the Reviewer for this insightful suggestion, which helped us to further understand the potential mechanism underlying the sex-specific increased progression of atherosclerosis in female Panx1LECdelApoe-/- mice. Following the suggestion of the Reviewer we show in the revised manuscript that 1) as compared to Panx1fl/flApoe-/- controls, the number of T lymphocytes is increased in advanced plaques of female Panx1LECdelApoe-/- mice but not in male mice of the same genotype (Figures 8E and 10E), and 2) the expression level of VCAM-1 was lower in Panx1-deficient LECs than in Panx1-expressing LECs isolated from lymph nodes of female mice (Figure 10F). Although we appreciate the suggestion to classify the populations of T lymphocytes in the blood, this requires fresh samples and thus new studies with 10 weeks high cholesterol diet on all groups of mice (40 mice), which was not possible in the 6 weeks given for the revision of our manuscript.

2) The authors should discuss why the observed sex differences occur, in terms of Panx1. The current draft provides extensive explanations regarding gender differences in dyslipidemia; however, as these do not lead to a definitive conclusion, they should be condensed. Instead, the discussion should focus on why there are gender differences in Panx1's contribution to atherosclerosis. It would be beneficial to examine the differences in Panx1 expression between males and females.

Response: The new results mentioned under the above point 1 are extensively discussed in the revised manuscript (page 20, lines 1-20), resulting in a better balance between the discussion on sex-differences in early atherosclerosis that are independent of Panx1 and the sex-differences in the progression of atherosclerosis, which involves Panx1 in LECs. As requested, we mention in the revised manuscript that Panx1 expression is higher in LECs of males (page 17, line 1), an observation that was already described in detail in our earlier study (Ehrlich et al., Physiol Rep 2024; reference 18 in this manuscript).

3) Lipoprotein cholesterol and triglycerides should be fractionated into at least VLDL, LDL, and HDL for evaluation. Merely assessing changes in total cholesterol is insufficient to rule out the involvement of dyslipidemia.

Response: As requested by the Reviewer, we have performed additional measurements and show now the serum LDL and HDL values (Figures 3C-D, 7C-D and 9C-D). Unfortunately, VLDL measurements are not possible on the Cobas C111 analyser available to us.

4) The two experimental strategies (initiation and progression) are not clearly linked to the figures, even in the legends. Please revise this for clarity.

Response: We thank the Reviewer for this suggestion. We revised the legends and the two experimental strategies are now clearly mentioned for all Figures (pages 23-25). In addition, we have critically revised the text of the manuscript and the title of the manuscript to better link results and strategies.

Reviewer 2

We thank the Reviewer for his/her comments on our manuscript.

The goal of this manuscript is to examine the impact of lymphatic endothelial Pannexin 1 (LEC Panx1) on the development and stability of atherosclerotic plaques. Despite being an intriguing subject, the data provided does not indicate a role for LEC Panx1 in atherosclerosis. New findings reveal variations in serum lipid levels, plaque size, and plaque vulnerability based on sex. However, these differences are not linked to the presence or absence of Panx1. Given the data presented, the significance of the results remains uncertain.

Response: We are happy to note that the Reviewer considers the subject of our study intriguing. Following the suggestions of Reviewer 1, we performed additional experiments to better understand the potential mechanism underlying the sex-specific increased progression of atherosclerosis female Panx1LECdelApoe-/- mice. We show in the revised manuscript that 1) as compared to Panx1fl/flApoe-/- controls, the number of T lymphocytes is increased in advanced plaques of female Panx1LECdelApoe-/- mice but not in male mice of the same genotype (Figures 8E and 10E), and 2) the expression level of VCAM-1 was lower in Panx1-deficient LECs than in Panx1-expressing LECs isolated from lymph nodes of female mice (Figure 10F). These new results mentioned are extensively discussed in the revised manuscript (page 20, lines 1-20), resulting in a better balance between the discussion on sex-differences in early atherosclerosis that are independent of Panx1 and the sex-differences in the progression of atherosclerosis, which involves Panx1 in LECs.

Journal Requirements

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?

Response: The manuscript has been formatted according to the template.

To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information regarding the experiments involving animals and ensure you have included details on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, and (3) efforts to alleviate suffering.

Response: All required details are in the methods section (page 7).

When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process.

Response: Once YARETA DOI has been finalized to make it publicly available, no further changes can be made. It is therefore advised to only do this for accepted manuscripts. We will do so immediately after acceptance of the manuscript and provide the DOI in the proofs of the manuscript.

4. Thank you for stating the following financial disclosure:

This study was supported by grants from the Swiss National Science Foundation (grant number 310030_182573 to BRK) and the Gabbiani fund (to AE).

Please state what role the funders took in the study. If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.""

Response: This statement has been included in the revised manuscript (page 22).

5. Thank you for stating the following in your Competing Interests section:

NO authors have competing interests.

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state ""The authors have declared that no competing interests exist."", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now

This information should be included in your cover letter; we will change the online submission form on your behalf.

Response: The above requested changes have been made (page 22).

Attachment

Submitted filename: Response to reviewers.pdf

pone.0315511.s001.pdf (82.3KB, pdf)

Decision Letter 1

Eliseo A Eugenin

27 Nov 2024

Protective role of Pannexin1 in lymphatic endothelial cells in the progression of atherosclerosis in female mice

PONE-D-24-40523R1

Dear Dr. Kwak,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Eliseo A Eugenin, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Dear Dr. Kwak:

Thank you for re-submitting your manuscript to PLOsone. The manuscript was evaluated by 2 experts in the field with excellent comments. Thank you for addressing all the comments.

Best Regards

Eliseo Eugenin

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have adequately addressed the concerns raised by this reviewer. There are no additional comments.

Reviewer #2: The authors have attempted to address my comments. The manuscript is written in an easy to understand manner.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Takuro Miyazaki

Reviewer #2: No

**********

Acceptance letter

Eliseo A Eugenin

13 Dec 2024

PONE-D-24-40523R1

PLOS ONE

Dear Dr. Kwak,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Eliseo A Eugenin

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to reviewers.pdf

    pone.0315511.s001.pdf (82.3KB, pdf)

    Data Availability Statement

    The source data that support the findings will be available in YARETA following acceptance of the manuscript.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES